Tripping the switch: p38 inhibition unlocks venetoclax and inotuzumab ozogamicin synergy

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-08-20
DOI
https://doi.org/10.3324/haematol.2026.301601
Primary Topic
Melanoma and MAPK Pathways
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tripping the switch: p38 inhibition unlocks venetoclax and inotuzumab ozogamicin synergy

Beat Bornhäuser, Alisson Charmey
Haematologica
Melanoma and MAPK Pathways
article

Tripping the switch: p38 inhibition unlocks venetoclax and inotuzumab ozogamicin synergy

Beat Bornhäuser, Alisson Charmey
article en

Abstract

No abstract available for this paper.
Haematologica
University Children's Hospital Zurich (CH)
Zero hunger
Openalex Percentile: Top 17%
Melanoma and MAPK Pathways
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.